Statistik Asas
| LEI | 529900J5ALF3JG921927 |
| CIK | 1345099 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mesoblast Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
exhbit992optiontoissueus Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 4/9/2025 The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued New class-code to be confirmed WARRANTS 3 5,000,000 Proposed +issue date 1/12/2025 Refer to next page for full details of the announcement A placement or other type of issue Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 2 / 5 Part 1 - Entity and announcement details 1. |
|
| September 4, 2025 |
exhbit991optiontoissueus MESOBLAST ENTERS INTO OPTION TO ISSUE US$50 MILLION CONVERTIBLE NOTES Melbourne, Australia; September 4 and New York, USA; September 3, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50. |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| August 29, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Mesoblast Limited (the “Company”) on Form 20-F for the year ended June 30, 2025 as filed on the date hereof (the “Report”), I, Andrew Chaponnel, Interim Chief Financial Officer for the Company, certify pursuant to 18 U.S.C. § 13 |
|
| August 29, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Silviu Itescu, certify that: 1.I have reviewed this annual report on Form 20-F of Mesoblast Limited (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or om |
|
| August 29, 2025 |
exhibit992 mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases August 2025 ASX: MSB; Nasdaq: MESO Financial Results and Operational Update for the Full Year Ended June 30, 2025 Exhibit 99. |
|
| August 29, 2025 |
Exhibit 99.1 Appendix 4E Preliminary final report for the twelve months to 30 June 2025 Name of entity MESOBLAST LIMITED ABN 68 109 431 870 1.Reporting period Report for the financial year ended 30 June 2025 Previous corresponding period is the financial year ended 30 June 2024 2.Results for announcement to the market Up/down % change Amount reported for the year ended 30 June 2025 USD’000 Revenue |
|
| August 29, 2025 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Chaponnel, certify that: (1)I have reviewed this annual report on Form 20-F of Mesoblast Limited (the “Company”); (2)Based on my knowledge, this report does not contain any untrue statement of a material fact |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (J |
|
| August 29, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-284705, 333-283799, 333-278727, 333-272029 and 333-268890) and Form S-8 (Nos. 333-210935, 333-220988, 333-240107, 333-261863 and 333-267663) of Mesoblast Limited of our report dated August 29, 2025 relating to the financial s |
|
| August 29, 2025 |
exhibit49 Executive Contract Mesoblast Limited ACN 109 431 870 Professor Silviu Itescu Exhibit 4. |
|
| August 29, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Mesoblast Limited (the “Company”) on Form 20-F for the year ended June 30, 2025 as filed on the date hereof (the “Report”) ”), I, Silviu Itescu, Chief Executive Officer for the Company, certify pursuant to 18 U.S.C. § 1350, as a |
|
| August 29, 2025 |
exhibit991 BANNER YEAR FOR MESOBLAST WITH FIRST FDA PRODUCT APPROVAL AND SUCCESSFUL COMMERCIAL LAUNCH OF RYONCIL® Financial Results and Operational Update for the Full Year Ended June 30, 2025 Melbourne, Australia; August 29 and New York, USA; August 28, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. |
|
| August 29, 2025 |
exhibit421 Lonza mesoblast [CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. |
|
| August 29, 2025 |
This page is required for Australian Disclosure Requirements and has been intentionally left blank. Exhibit 99.2 This page is required for Australian Disclosure Requirements and has been intentionally left blank. |
|
| August 27, 2025 |
exhibit991 MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST Melbourne, Australia; August 27 and New York, USA; August 26, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025. |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (J |
|
| July 18, 2025 |
SUCCESSFUL COMMERCIAL LAUNCH OF RYONCIL® Activity Report for Quarter Ended June 30, 2025 (Appendix 4C) Melbourne, Australia: July 18 and New York, USA: July 17, 2025: Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first quarter post product launch. |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| July 15, 2025 |
exhibit992 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Monday July 14, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transf |
|
| July 15, 2025 |
Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday July 14, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation MSBAI OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 483,254 Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied 30/06/2025 Refer to next page for full details of the announcement Exhibit 99. |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| July 15, 2025 |
exhibit994 Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday July 14, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date MSB ORDINARY FULLY PAID 2,185,000 27/06/2025 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer Exhibit 99. |
|
| July 15, 2025 |
exhibit993 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Monday July 14, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MSB ORDINARY FULLY PAID 2,253,923 30/06/2025 Refer to next page for full details of the announcement Unquoted options that have been exercised or other unquoted +convertible securities that have been converted Exhibit 99. |
|
| July 1, 2025 |
MESOBLAST AND FDA ALIGN ON KEY ITEMS FOR REVASCOR® BIOLOGIC LICENSE APPLICATION IN ISCHEMIC HEART FAILURE Melbourne, Australia; July 1 and New York, USA; June 30, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| June 12, 2025 |
MESOBLAST MAINTAINS MOMENTUM WITH FDA ON ACCELERATED APPROVAL PATHWAY FOR REVASCOR® IN ISCHEMIC HEART FAILURE AND LABEL EXTENSION FOR RYONCIL® IN ADULTS WITH GVHD Melbourne, Australia; June 12 and New York, USA; June 11, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States |
|
| May 15, 2025 |
exhibit991ryoncilfdaexcl FDA PROVIDES SEVEN YEARS OF ORPHAN-DRUG EXCLUSIVE APPROVAL FOR RYONCIL® Melbourne, Australia; May 15 and New York, USA; May 14, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Juri |
|
| April 30, 2025 |
APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED MARCH 31, 2025 Melbourne, Australia: April 30 and New York, USA: April 29, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 29, 2025 |
MESOBLAST APPOINTS CORPORATE FINANCE LEADER LYN COBLEY TO BOARD Melbourne, Australia; April 29 and New York, USA; April 28, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. |
|
| April 29, 2025 |
Appendix 3X Initial Director’s Interest Notice + See chapter 19 for defined terms. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 24, 2025 |
Gregory George Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity MESOBLAST LIMITED ABN 68 109 431 870 We (the entity) give ASX the following information under listin |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 17, 2025 |
MESOBLAST EXTENDS PAYER COVERAGE FOR RYONCIL® TO OVER 100 MILLION US LIVES Melbourne, Australia; April 17 and New York, USA; April 16, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U. |
|
| April 15, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Monday April 14, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MSB ORDINARY FULLY PAID 8,184,336 27/03/2025 Refer to next page for full details of the announcement Unquoted options that have been exercised or other unquoted +convertible securities that have been converted Exhibit 99. |
|
| April 15, 2025 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday April 14, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date MSB ORDINARY FULLY PAID 7,255,000 31/03/2025 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer Exhibit 99. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 15, 2025 |
Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday April 14, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation MSBAI OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 30,000 Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied 31/03/2025 Refer to next page for full details of the announcement Exhibit 99. |
|
| April 15, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Monday April 14, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MSBAI OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 7,275,000 01/04/2025 Refer to next page for full details of the announcement +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Exhibit 99. |
|
| April 9, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Tuesday April 08, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MSBAI OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 4,839,000 01/04/2025 Refer to next page for full details of the announcement +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Exhibit 99. |
|
| April 9, 2025 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 4, 2025 |
MESOBLAST ALLOGENEIC CELL THERAPY PRODUCTS ARE DESIGNATED ‘U.S. COUNTRY OF ORIGIN’ AND NOT SUBJECT TO U.S. TARIFFS Melbourne, Australia; April 4 and New York, USA; April 3, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tarif |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 3, 2025 |
MESOBLAST FILES REQUEST FOR TYPE B MEETING WITH FDA TO DISCUSS ACCELERATED APPROVAL PATHWAY FOR REVASCOR® IN ISCHEMIC HEART FAILURE Melbourne, Australia; April 3 and New York, USA; April 2, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 31, 2025 |
FIRST THREE CHILDREN TO COMMENCE TREATMENT WITH RYONCIL® UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) MANDATES RYONCIL® COVERAGE Melbourne, Australia; March 31 and New York, USA; March 30, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U. |
|
| March 27, 2025 |
RYONCIL® IS NOW AVAILABLE FOR PURCHASE IN THE UNITED STATES Melbourne, Australia; March 27 and New York, USA; March 26, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 14, 2025 |
RYONCIL® PRODUCT INFORMATION NOW AVAILABLE IN ALL FOUR MAJOR DRUG PRICING COMPENDIA IN UNITED STATES Melbourne, Australia; March 14 and New York, USA; March 13, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four major drug pricing compendia in the United States. |
|
| March 13, 2025 |
Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity MESOBLAST LIMITED ABN 68 109 431 870 We (the entity) give ASX the following information under listing rule 3.19A.2 |
|
| March 13, 2025 |
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases March 2025 ASX: MSB; Nasdaq: MESO Presentation at ISCT Ryoncil® - The First FDA Approved Mesenchymal Stromal Cell Therapy Exhibit 99. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 12, 2025 |
MESOBLAST CEO TO DELIVER FEATURED PRESENTATION AT ISCT NORTH AMERICA VIRTUAL TOWN HALL Melbourne, Australia; March 12 and New York, USA; March 12, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Silviu Itescu will deliver the Featured Presentation at the International Cell & Gene Therapy (ISCT) North America Regional Virtual Town Hall at 4. |
|
| March 7, 2025 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| March 7, 2025 |
MESOBLAST ADDED TO S&P/ASX200 INDEX Melbourne, Australia; March 6 and New York, USA; March 5, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective prior to the open of trading today on the Australian Stock Exchange (ASX). |
|
| March 7, 2025 |
7 March 2025 Dr Gregory George – Appendix 3Y and replacement 3X Please see attached an Appendix 3Y for recent share purchases by recently appointed director Dr George. |
|
| March 7, 2025 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| March 7, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Friday March 07, 2025 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MSB ORDINARY FULLY PAID 548,851 28/02/2025 Refer to next page for full details of the announcement Unquoted options that have been exercised or other unquoted +convertible securities that have been converted Exhibit 99. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| February 28, 2025 |
exhibit991 MESOBLAST SETS RYONCIL® PRICE BASED ON ECONOMIC VALUE OF TREATMENT WITH PLANNED PRODUCT AVAILABILITY THIS QUARTER Financial Results and Operational Update for Half-Year Ended December 31, 2024 Melbourne, Australia; February 27 and New York, USA; February 26, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024, ”Our FDA approved product Ryoncil® will be available in the coming weeks to the children with SR- aGvHD in need of life-saving therapy,” said Dr. |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| February 28, 2025 |
exhibit992 mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases February 2025 ASX: MSB; Nasdaq: MESO Financial Results and Operational Update for the Half Year Ended December 31, 2024 Exhibit 99. |
|
| February 27, 2025 |
PricewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001 T: 61 3 8603 1000, F: 61 3 8603 1999, www. |
|
| February 27, 2025 |
exhibit991app4d Exhibit 99.1 Mesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2024 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended June 30, 2024. -2- Rule 4.2A.3 Appendix 4D Half-Year Report for the six mon |
|
| February 27, 2025 |
PricewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001 T: 61 3 8603 1000, F: 61 3 8603 1999, www. |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Filed in the month of February 2025 for the period ended December 31, 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applica |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| February 25, 2025 |
Appendix 3X Initial Director’s Interest Notice + See chapter 19 for defined terms. |
|
| February 25, 2025 |
DR. GREGORY GEORGE MD PhD JOINS MESOBLAST BOARD Melbourne, Australia; February 24 and New York, USA; February 23, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors. Dr. George founded and managed the larg |
|
| February 14, 2025 |
RYONCIL® FDA APPROVAL AND MARKET LAUNCH HIGHLIGHTED AT TANDEM TRANSPLANTATION MEETINGS Melbourne, Australia; February 14 and New York, USA; February 13, 2025: Mesoblast Limited (ASX:MSB;Nasdaq:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product Ryoncil® (remestemcel-L) is being highlighted at the 2025 Transplantation & Cellular Therapy Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR), the industry’s premier conference taking place this week in Honolulu, HI. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| February 12, 2025 |
Mesoblast Limited 34,675,000 Ordinary Shares represented by 3,467,500 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-284705 Prospectus Mesoblast Limited 34,675,000 Ordinary Shares represented by 3,467,500 American Depositary Shares In January 2025, Mesoblast Limited sold 104,000,000 ordinary shares to institutional and professional investors, including the persons identified in this prospectus (the “Shareholders”), in exchange for proceeds of approximately A$ |
|
| February 10, 2025 |
Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Australia February 10, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 6, 2025 |
As filed with the Securities and Exchange Commission on February 6, 2025 As filed with the Securities and Exchange Commission on February 6, 2025 Registration No. |
|
| February 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Mesoblast Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Aggregate Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares 457(c) 34,675,000 $ 1. |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Mesoblast Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Aggregate Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares 457(c) 34,675,000 $ 1. |
|
| February 5, 2025 |
As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 31, 2025 |
exhibit991 APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2024 Melbourne, Australia: January 31 and New York, USA: January 30, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second quarter ended December 31, 2024. |
|
| January 31, 2025 |
exhibit992 RYONCIL® COMMERCIAL LAUNCH UPDATE AND PRODUCT PIPELINE Melbourne, Australia; January 31 and New York, USA; January 30, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U. |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 24, 2025 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| January 24, 2025 |
Exhibit 99.3 |
|
| January 24, 2025 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday January 24, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date MSB ORDINARY FULLY PAID 3,225,000 24/01/2025 Refer to next page for full details of the announcement +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Exhibit 99. |
|
| January 24, 2025 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday January 17, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date MSB ORDINARY FULLY PAID 97,680,000 20/01/2025 Refer to next page for full details of the announcement +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Exhibit 99. |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 16, 2025 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday January 10, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted |
|
| January 16, 2025 |
Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 6/1/2025 The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued MSB ORDINARY FULLY PAID 10,228,239 Proposed +issue date 7/1/2025 Refer to next page for full details of the announcement A placement or other type of issue F or p er so na l u se o nl y Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 2 / 5 Part 1 - Entity and announcement details 1. |
|
| January 16, 2025 |
Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 14/1/2025 The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued MSB ORDINARY FULLY PAID 104,000,000 Proposed +issue date 20/1/2025 Refer to next page for full details of the announcement A placement or other type of issue F or p er so na l u se o nl y Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 2 / 5 Part 1 - Entity and announcement details 1. |
|
| January 16, 2025 |
MESOBLAST RAISES NEW CAPITAL FOR COMMERCIAL LAUNCH OF RYONCIL® Not for release to US wire services or distribution in the United States Melbourne, Australia; January 14 and New York, USA; January 13, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising A$260 million (US$160 million) at A$2. |
|
| January 16, 2025 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday January 10, 2025 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted |
|
| December 27, 2024 |
Mesoblast Limited 2,000,000 Ordinary Shares represented by 200,000 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-283799 Prospectus Mesoblast Limited 2,000,000 Ordinary Shares represented by 200,000 American Depositary Shares This prospectus relates to the offer and sale from time to time by the person identified in this prospectus (the “Shareholder”) of up to 2,000,000 ordinary shares of Mesoblast Limited, represented by 200,000 American Depositary Shares |
|
| December 23, 2024 |
Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Australia December 23, 2024 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 23, 2024 |
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Friday December 20, 2024 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date MSB ORDINARY FULLY PAID 5,039,814 13/12/2024 Refer to next page for full details of the announcement +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B F or p er so na l u se o nl y Exhibit 99. |
|
| December 23, 2024 |
As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| December 23, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| December 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Mesoblast Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Aggregate Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares 457(c) 2,000,000 $ 1. |
|
| December 20, 2024 |
MESOBLAST’S RYONCIL® IS THE FIRST U.S. FDA-APPROVED MESENCHYMAL STROMAL CELL (MSC) THERAPY • RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. • RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR- aGvHD), a life-threatening condition with |
|
| December 20, 2024 |
MESOBLAST TO BE ADDED TO NASDAQ BIOTECHNOLOGY INDEX Melbourne, Australia; December 18 and New York, USA; December 17, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| December 16, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 mesoblast-sc13ga121624.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Authorized to Re |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Mesoblast Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Aggregate Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares 457(c) 2,000,000 $ 1. |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| December 9, 2024 |
FDA GRANTS REVASCOR® (REXLEMESTROCEL-L) REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION IN CHILDREN WITH CONGENITAL HEART DISEASE Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Melbourne, Australia; December 5 and New York, USA; December 4, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| December 4, 2024 |
REVASCOR IMPROVES SURVIVAL AND REDUCES MAJOR MORBIDITY IN HIGH-RISK ISCHEMIC HEART FAILURE PATIENTS WITH INFLAMMATION Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Melbourne, Australia; December 3 and New York, USA; December 2, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cell |
|
| November 18, 2024 |
15 November 2024 Mesoblast Limited (MSB) Results of Annual General Meeting Held 15 November 2024 In accordance with ASX Listing Rule 3. |
|
| November 18, 2024 |
CHAIR’S ADDRESS TO SHAREHOLDERS 2024 ANNUAL GENERAL MEETING Good afternoon shareholders. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| November 18, 2024 |
Appendix 3Z Final Director’s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Mesoblast Limited ABN 68 |
|
| November 18, 2024 |
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases November 2024 ASX: MSB; Nasdaq: MESO Annual General Meeting 2024 Exhibit 99. |
|
| November 13, 2024 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Tuesday November 12, 2024 The +securities the subject of this notification are: Total number of +securities to be issued/transferred |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| November 1, 2024 |
exhibit991 APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2024 Melbourne, Australia: October 31 and New York, USA: October 30, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024. |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| October 18, 2024 |
Exhibit 99.4 |
|
| October 18, 2024 |
Exhibit 99.5 |
|
| October 18, 2024 |
For the Annual General Meeting of the Company to be held at: Time: 12.00 noon (Melbourne time, AEDT) Date: Friday, 15 November 2024 Place: MinterEllison Collins Arch, Level 20 447 Collins Street Melbourne Victoria 3000 Notice of Annual General Meeting and Explanatory Memorandum Mesoblast Limited ABN 68 109 431 870 THIS IS AN IMPORTANT DOCUMENT If you are in doubt as to what to do with this documen |
|
| October 18, 2024 |
exhibit993 Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Mesoblast Limited ABN/ARBN Financial year ended: 109 431 870 30 June 2024 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on o |
|
| October 18, 2024 |
M ESO B LA ST LIM ITED A N N U A L R EPO RT 2024 ANNUAL REPORT 2024 GLOBAL LEADER IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASES Exhibit 99. |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| October 9, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 mesoblast-sc13ga100924.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Authorized to Re |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| October 1, 2024 |
MESOBLAST OPTION TO ISSUE UP TO US$50 MILLION CONVERTIBLE NOTES FOR PRODUCT LAUNCH Melbourne, Australia; September 30 and New York, USA; September 29, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for issue, at its sole discretion, up to US$50. |
|
| October 1, 2024 |
Exhibit 99.2 |
|
| August 29, 2024 |
exhibit991 MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL UPDATE FOR FISCAL YEAR ENDED JUNE 30, 2024 Potential first product approval and preparing for commercial launch Melbourne, Australia; August 29 and New York, USA; August 28, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. |
|
| August 29, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Chaponnel, certify that: (1)I have reviewed this annual report on Form 20-F of Mesoblast Limited (the “Company”); (2)Based on my knowledge, this report does not contain any untrue statement of a material fact |
|
| August 29, 2024 |
This page is required for Australian Disclosure Requirements and has been intentionally left blank. Exhibit 99.2 This page is required for Australian Disclosure Requirements and has been intentionally left blank. |
|
| August 29, 2024 |
Exhibit 99.1 Appendix 4E Preliminary final report for the twelve months to 30 June 2024 Name of entity MESOBLAST LIMITED ABN 68 109 431 870 1.Reporting period Report for the financial year ended 30 June 2024 Previous corresponding period is the financial year ended 30 June 2023 2.Results for announcement to the market Up/down % change Amount reported for the year ended 30 June 2024 USD’000 Revenue |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (J |
|
| August 29, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Silviu Itescu, certify that: 1.I have reviewed this annual report on Form 20-F of Mesoblast Limited (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or om |
|
| August 29, 2024 |
FIFTH AMENDMENT TO LOAN AGREEMENT AND GUARANTY EXECUTION VERSION Exhibit 4.29 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FIFTH AMENDMENT TO LOAN AGREEMENT AND GUARANTY This Fifth Amendment to Loan Agreement and Guaranty (this “Amendme |
|
| August 29, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Mesoblast Limited (the “Company”) on Form 20-F for the year ended June 30, 2024 as filed on the date hereof (the “Report”), I, Andrew Chaponnel, Interim Chief Financial Officer for the Company, certify pursuant to 18 U.S.C. § 13 |
|
| August 29, 2024 |
Level 23 Rialto Towers 525 Collins Street Melbourne Vic 3000 Australia DX 204 Melbourne T +61 3 8608 2000 F +61 3 8608 1000 minterellison. |
|
| August 29, 2024 |
Exhibit 4.2 Execution Version 138646562.2 AMENDMENT NO. 1, dated as of January 9, 2024 (the “Amendment”), to the Amended and Restated Deposit Agreement, dated as of October 19, 2015, (as previously amended, the “Deposit Agreement”, among MESOBLAST LIMITED and its successors (the “Company”), JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of A |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
|
| August 29, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Mesoblast Limited (the “Company”) on Form 20-F for the year ended June 30, 2024 as filed on the date hereof (the “Report”) ”), I, Silviu Itescu, Chief Executive Officer for the Company, certify pursuant to 18 U.S.C. § 1350, as a |
|
| August 29, 2024 |
exhibit992 mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases August 2024 ASX: MSB; Nasdaq: MESO Financial Results and Operational Update for the Year Ended June 30, 2024 Exhibit 99. |
|
| August 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-278727, 333-272029, 333-270814, 333-262301, 333-267175 and 333-268890) and Form S-8 (Nos. 333-210935, 333-220988, 333-240107, 333-261863 and 333-267663) of Mesoblast Limited of our report dated August 29, 2024 relating to the |
|
| August 29, 2024 |
Confidential 15 September 2023 Professor Silviu Itescu Managing Director & Chief Executive Officer Mesoblast Ltd By email: [*] RE: Amendment to employment agreement - remuneration Dear Silviu: I refer to: (i) your employment agreement dated 8 August 2014 (“Agreement”) as Managing Director and Chief Executive Officer of Mesoblast Limited (“Company”); and (ii) the resolution of the Board on 28 August 2023 regarding the payment of your remuneration (“Resolution”). |
|
| August 29, 2024 |
Mesoblast Limited Policy on Recovery of Erroneously Awarded Incentive Compensation 1. |
|
| August 1, 2024 |
{00876702} APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED JUNE 30, 2024 Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD Melbourne, Australia; July 31 and New York, USA; July 30, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the fourth quarter ended June 30, 2024. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (J |
|
| July 25, 2024 |
FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENSE APPLICATION (BLA) FOR RYONCIL® IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS- HOST DISEASE (SR-aGVHD) If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Cell Therapy for Children Up To 18 Years Old with SR-aGVHD. |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| July 23, 2024 |
PATIENT ENROLLMENT COMMENCED IN PIVOTAL PHASE 3 TRIAL OF REXLEMESTROCEL-L FOR CHRONIC LOW BACK PAIN Melbourne, Australia; July 22 and New York, USA; July 21, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product rexlemestrocel-L in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease of less than five years duration has commenced enrollment at multiple sites across the United States. |
|
| July 23, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| July 11, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) 9 July 2024 (Date of Event wh |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| July 10, 2024 |
{00876702} MESOBLAST RESUBMITS BIOLOGICS LICENSE APPLICATION (BLA) WITH UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) FOR APPROVAL OF RYONCIL® IN CHILDREN WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS- HOST DISEASE (SR-aGVHD) Melbourne, Australia; July 9 and New York, USA; July 8, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil® (remestemcel-L) in the treatment of children with SR-aGVHD. |
|
| July 2, 2024 |
MESOBLAST TO FILE BIOLOGICS LICENSE APPLICATION FOR RYONCIL® FDA APPROVAL NEXT WEEK Melbourne, Australia; July 1 and New York, USA; July 1, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U. |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Jur |
|
| June 4, 2024 |
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases May 2024 ASX: MSB; Nasdaq: MESO Corporate Presentation E x h i b i t 9 9 . |
|
| June 4, 2024 |
{00876702} MESOBLAST CORPORATE PRESENTATION AT INVESTOR CONFERENCE Melbourne, Australia; June 3 and New York, USA; June 2, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. |
|
| May 10, 2024 |
6-K 1 a2024-05x10ericrosesharepu.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Regist |
|
| May 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| May 3, 2024 |
SC 13G/A 1 mesoblast-sc13ga050324.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Authorized to Re |
|
| May 3, 2024 |
exhibit991 Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Juri |
|
| May 1, 2024 |
MESOBLAST CHAIR TRANSITION Melbourne, Australia; April 30 and New York, USA; April 29, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Joseph R. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Juri |
|
| May 1, 2024 |
{00876702} APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED MARCH 31, 2024 FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure Melbourne, Australia; April 30 and New York, USA; April 29, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. |
|
| April 26, 2024 |
Mesoblast Limited 58,000,000 Ordinary Shares represented by 5,800,000American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-278727 Prospectus Mesoblast Limited 58,000,000 Ordinary Shares represented by 5,800,000American Depositary Shares This prospectus relates to the offer and sale from time to time by the persons identified in this prospectus (the “Shareholders”) of up to 58,000,000 ordinary shares of Mesoblast Limited, represented by 5,800,000 American Depositary |
|
| April 22, 2024 |
Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000 Australia April 22, 2024 via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 17, 2024 |
exhibit991appendix3h-not Appendix 3H - Notification of cessation of securities Appendix 3H - Notification of cessation of securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday April 15, 2024 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +sec |
|
| April 17, 2024 |
exhibit991appendix2a-app Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Tuesday April 16, 2024 The +securities to be quoted are: Total number of +securities to be quoted ASX +security code Security description Number of + |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 17, 2024 |
exhbit991appendix3g-noti Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Tuesday April 16, 2024 The +securities the subject of this notification are: Total number of +securities to |
|
| April 17, 2024 |
exhibit991appendix3y-cha Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| April 16, 2024 |
As filed with the Securities and Exchange Commission on April 16, 2024 As filed with the Securities and Exchange Commission on April 16, 2024 Registration No. |
|
| April 16, 2024 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Mesoblast Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Aggregate Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares 457(c) 58,000,000 $ 0. |
|
| April 9, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0203520-13ga1georgemeso.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Author |
|
| April 3, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0203232-13ga3georgemeso.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Author |
|
| March 27, 2024 |
exhibit991fdanotifiescli {00876702} UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) NOTIFIES MESOBLAST THAT AVAILABLE CLINICAL DATA FROM PHASE 3 TRIAL APPEAR SUFFICIENT TO SUPPORT BLA SUBMISSION FOR REMESTEMCEL-L IN CHILDREN WITH STEROID- REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-aGVHD) Melbourne, Australia; March 26 and New York, USA; March 25, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 21, 2024 |
Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 14/3/2024 The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued MSB ORDINARY FULLY PAID 5,039,814 Proposed +issue date 30/12/2024 Refer to next page for full details of the announcement A placement or other type of issue F or p er so na l u se o nl y Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 2 / 5 Part 1 - Entity and announcement details 1. |
|
| March 21, 2024 |
Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement 20/3/2024 The Proposed issue is: Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be issued MSB ORDINARY FULLY PAID 3,100,000 Proposed +issue date 25/3/2024 Refer to next page for full details of the announcement A placement or other type of issue F or p er so na l u se o nl y Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 2 / 5 Part 1 - Entity and announcement details 1. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 21, 2024 |
This appendix is available as an online form Only use this form if the online version is not available Rule 2. |
|
| March 20, 2024 |
AU:MSB / Mesoblast Limited / George Gregory - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0202182-13ga2georgemeso.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mesoblast Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 590717104 (CUSIP Number) See Item 2(b) below (Name, Address and Telephone Number of Person Author |
|
| March 15, 2024 |
exhibit991 MESOBLAST SUCCESSFULLY COMPLETES PLACEMENT AND ACCELERATED ENTITLEMENT OFFER Melbourne, Australia; March 14 and New York, USA; March 13, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non- renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 12, 2024 |
{00876702} UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) SUPPORTS ACCELERATED APPROVAL PATHWAY FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE (LVAD) Melbourne, Australia; March 11 and New York, USA; March 10, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia (Ju |
|
| March 1, 2024 |
exhibit991hy1fy24results MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL UPDATE FOR HALF-YEAR ENDED DECEMBER 31, 2023 Melbourne, Australia; February 29 and New York, USA; February 28, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. |
|
| March 1, 2024 |
exhibit992hy1fy24results mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases February 2024 ASX: MSB; Nasdaq: MESO Financial Results and Operational Update for the Half-Year Ended December 31, 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. |
|
| February 29, 2024 |
PricewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001 T: 61 3 8603 1000, F: 61 3 8603 1999 Liability limited by a scheme approved under Professional Standards Legislation. |
|
| February 29, 2024 |
exhibit991app4d Exhibit 99.1 Mesoblast Limited ABN 68 109 431 870 and Controlled Entities (Mesoblast Group) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED DECEMBER 31, 2023 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A This half-year financial report is to be read in conjunction with the financial report for the period ended June 30, 2023. -2- Rule 4.2A.3 Appendix 4D Half-Year Report for the six mon |
|
| February 29, 2024 |
PricewaterhouseCoopers, ABN 52 780 433 757 2 Riverside Quay, SOUTHBANK VIC 3006, GPO Box 1331, MELBOURNE VIC 3001 T: 61 3 8603 1000, F: 61 3 8603 1999, www. |
|
| February 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Filed in the month of February 2024 for the period ended December 31, 2023 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applica |
|
| February 21, 2024 |
exhibit991 {00876702} UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE Melbourne, Australia; February 15 and New York, USA; February 14, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) an Orphan-Drug Designation (ODD) following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| February 1, 2024 |
{00876702} APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023 Melbourne, Australia; January 31 and New York, USA; January 30, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023. |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 23, 2024 |
{00876702} UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open Melbourne, Aust |
|
| January 16, 2024 |
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities Notification of Issue, Conversion or Payment up of Unquoted Equity Securities 1 / 7 Announcement Summary Entity name MESOBLAST LIMITED Date of this announcement Monday January 15, 2024 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security de |
|
| January 16, 2024 |
Notification of cessation of +securities Notification of cessation of +securities 1 / 5 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Monday January 15, 2024 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation MSBA |
|
| January 16, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 5, 2024 |
This appendix is available as an online form Only use this form if the online version is not available +Rule 2. |
|
| January 5, 2024 |
Notification of cessation of +securities Notification of cessation of +securities 1 / 4 Announcement Summary Entity name MESOBLAST LIMITED Announcement Type New announcement Date of this announcement Thursday December 28, 2023 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation MSBAJ INCENTIVE RIGHTS 1,500,000 Expiry of option or other convertible security without exercise or conversion 28/12/2023 Refer to next page for full details of the announcement F or p er so na l u se o nl y Notification of cessation of +securities Notification of cessation of +securities 2 / 4 Part 1 - Announcement Details 1. |
|
| January 5, 2024 |
UPDATE ON INSTITUTIONAL PLACEMENT AND ENTITLEMENT OFFER Melbourne, Australia; December 28, 2023: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its Institutional Placement and 1 for 4 pro-rata accelerated non-renounceable entitlement offer (Entitlement Offer). |
|
| January 5, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 4, 2024. As filed with the U.S. Securities and Exchange Commission on January 4, 2024. Registration No. 333-273532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MESOBLAST LIMITED (Exact name of issuer of deposited securi |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 5, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| January 5, 2024 |
Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| January 5, 2024 |
Exhibit (a)(2) AMENDMENT NO. 1, dated as of , 2024 (the “Amendment”), to the Amended and Restated Deposit Agreement, dated as of October 19, 2015, (as previously amended, the “Deposit Agreement”, among MESOBLAST LIMITED and its successors (the “Company”), JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of America, as depositary hereunder |
|
| January 5, 2024 |
exhibit991adrratiochange {00876702} MESOBLAST MODIFIES RATIO FOR AMERICAN DEPOSITARY RECEIPT PROGRAM Mesoblast is consolidating the number of American Depositary Receipt (“ADR”) on issue which trade on Nasdaq by implementing a ratio change for its ADR program from 5 ordinary shares representing 1 ADR (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADR (10:1 ratio). |
|
| January 5, 2024 |
Exhibit (e) Rule 466 Certification The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: i. That it previously had filed a registration statement on Form F-6 (File No. 333-207378), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Post-Effective Amendment No. 4 to Form F-6 Registration |
|
| December 22, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 21, 2023. As filed with the U.S. Securities and Exchange Commission on December 21, 2023. Registration No. 333-273532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MESOBLAST LIMITED (Exact name of issuer of deposited secu |
|
| December 22, 2023 |
Exhibit (e) Rule 466 Certification The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: i. That it previously had filed a registration statement on Form F-6 (File No. 333-207378), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Post-Effective Amendment No. 2 to Form F-6 Registration |
|
| December 22, 2023 |
Exhibit (e) Rule 466 Certification The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: i. That it previously had filed a registration statement on Form F-6 (File No. 333-207378), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Post-Effective Amendment No. 3 to Form F-6 Registration |
|
| December 22, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 22, 2023. As filed with the U.S. Securities and Exchange Commission on December 22, 2023. Registration No. 333-273532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MESOBLAST LIMITED (Exact name of issuer of deposited secu |
|
| December 22, 2023 |
Exhibit (a)(3) [FORM OF FACE OF ADR] No. of ADSs: Number Each ADS represents Ten (10) Shares CUSIP: AMERICAN DEPOSITARY RECEIPT evidencing AMERICAN DEPOSITARY SHARES representing ORDINARY SHARES of MESOBLAST LIMITED (Incorporated under the laws of the Commonwealth of Australia) JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of America, as de |
|
| December 22, 2023 |
Exhibit (a)(2) AMENDMENT NO. 1, dated as of , 202 (the “Amendment”), to the Amended and Restated Deposit Agreement, dated as of October 19, 2015, (as previously amended, the “Deposit Agreement”, among MESOBLAST LIMITED and its successors (the “Company”), JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of America, as depositary hereunder ( |
|
| December 21, 2023 |
Exhibit (e) Rule 466 Certification The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: i. That it previously had filed a registration statement on Form F-6 (File No. 333-207378), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Post-Effective Amendment No. 1 to Form F-6 Registration |
|
| December 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 20, 2023. As filed with the U.S. Securities and Exchange Commission on December 20, 2023. Registration No. 333-273532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MESOBLAST LIMITED (Exact name of issuer of deposited secu |
|
| December 21, 2023 |
Exhibit (a)(2) AMENDMENT NO. 1, dated as of , 202 (the “Amendment”), to the Amended and Restated Deposit Agreement, dated as of October 19, 2015, (as previously amended, the “Deposit Agreement”, among MESOBLAST LIMITED and its successors (the “Company”), JPMORGAN CHASE BANK, N.A., a national banking association organized under the laws of the United States of America, as depositary hereunder (in s |
|
| November 29, 2023 |
{00876702} MESOBLAST FILES FOR ORPHAN DRUG AND PEDIATRIC RARE DISEASE DESIGNATIONS FOR REXLEMESTROCEL-L AS TREATMENT FOR SEVERE CONGENITAL HEART DISEASE Melbourne, Australia; November 27 and New York, USA; November 26, 2023: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). |
|
| November 29, 2023 |
28 November 2023 Mesoblast Limited (MSB) Results of Annual General Meeting Held 28 November 2023 In accordance with ASX Listing Rule 3. |
|
| November 29, 2023 |
{00876702} CHAIRMAN’S ADDRESS TO SHAREHOLDERS 2023 ANNUAL GENERAL MEETING Good afternoon shareholders. |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| November 29, 2023 |
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases November 2023 ASX: MSB; Nasdaq: MESO Annual General Meeting 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia |
|
| November 24, 2023 |
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases November 2023 ASX: MSB; Nasdaq: MESO Corporate Presentation CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. |
|
| November 24, 2023 |
{00876702} MESOBLAST PARTNERS WITH BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK (BMT CTN) ON PIVOTAL TRIAL IN ADULTS WITH SR-aGVHD Melbourne, Australia; November 22 and New York, USA; November 21, 2023: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD). |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
|
| November 1, 2023 |
{00876702} APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023 Melbourne, Australia; October 31 and New York, USA; October 30, 2023: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023. |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Australia ( |
